Connecting Molecules to Medicine™

See What Makes Nexus Pharmaceuticals Different

Through our commitment to innovative R&D, Nexus Pharmaceuticals identifies off-patent and difficult to formulate molecules that can be developed, improved upon, and commercialized to advance industry standards and deliver on critical medical needs.

Is your pharmaceutical manufacturer a certified diverse supplier?

New State-of-the-Art Manufacturing Facility located in Pleasant Prairie, WI 

Commitment to Quality
From Molecules to Medicine

Opening in Summer 2021

State-of-the-Art Sterile Injectable Manufacturing Facility

Located in Pleasant Prairie, Wisconsin, we broke ground in 2019 to build Project Tomorrow, a state-of-the-art sterile injectable manufacturing facility to support the production and supply of injectable drugs in various therapeutic areas including anesthesiology, oncology, cardiology, and neurology. We plan to invest $250 million over the next ten years and create over 400 jobs in total.

News

Nexus Pharmaceuticals Receives Patent for EMERPHED®

Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, has received a patent covering applications of EMERPHED® Ready-To-Use Ephedrine Sulfate Injection, the first FDA-approved premixed ephedrine in a ready-to-use 50 mg/10 mL vial. The United States Patent and Trademark Office (USPTO) issued the patent, U.S. Patent No. 11,090,278, on August 17, 2021.

read more

Nexus Pharmaceuticals Celebrates Grand Opening of New Facility

On Friday, July 16, 2021, Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, celebrated the opening of Project Tomorrow—the company’s new, state-of-the-art manufacturing facility in Pleasant Prairie, Wisconsin. Wisconsin Governor Tony Evers and U.S. Representative Bryan Steil (WI-01) attended the Project Tomorrow Grand Opening event.

read more

Find out what we’re about

Discover more about Nexus Pharmaceuticals and get in touch today!